What do we do at BIOLOGIC pharmamedical?

BIOLOGIC pharmamedical is involved in the research and development of nutrient- and nutraceutical- based technologies or analogues of these natural compounds using pharmaceutical or medical research models to help define how they interact and modulate cell signalling and behaviour. The genomic influences and proteomic changes induced by these botanical extracts and their molecular constituents are identified and mapped and then related to disease pathology.

An understanding of how these biomarkers are influenced by these natural medicinal agents either by phosphorylation, ubiquitination, acetylation or methylation; by degradation or by transcriptional or translational influences, for example, helps us map a path upstream and downstream of the target to unravel the full scope of a natural medicine’s potential. The ultimate objective is to gain a better understanding of the mechanisms involved in the pharmacology in order to produce a more effective and selective drug design that is repeatable, reliable and safe.

Why study natural medicines in the context of current pharmaceutical models?

Allopathic medicine centers on drug selectivity to improve drug effectiveness and reduce drug side-effects and contraindications. Such selectivity also plays a supportive role in patent viability and drug reliability. Natural compounds, even if isolated and concentrated are often comprised of sub-fractions that can contribute to a polypharmacology that does not fit the selectivity model.

In order to better predict the biological activity and potential interactivity of these multi-factorial natural medicinal agents the sub-fractions common to the natural extracts need to be studied individually as sequestered molecules and characterized in isolation. This compartmentalized information allows us to better understand the complex activity of the extract in its natural form but it also allows us an opportunity to splice out specific activity that is more selective for a desired membrane, cytoplasmic or nuclear target. With this information we gain the knowledge of the underpinnings for improved drug design with natural agents – the isolated fractions and/or their combinations.

How does this work at BIOLOGIC pharmamedical benefit us as a community – practitioners and patients?

Research at BIOLOGIC pharmamedical is being conducted to evaluate the modulation of various cell-surface and subcellular proteins by botanical extracts and their isolated sub-fractions to better understand the more selective activity of each component comprising even the most concentrated of extracts. Various biological models are used and multiple cell surface, proteomic and genomic targets are pursued. To this date we have revised the description of common natural drug mechanisms and how they modulate multiple cell signalling pathways; and often even how multiple points of activity can be focused on one signalling pathway. We have also identified novel patentable activity in multiple cases using this model.

This work can often lead to a completely new understanding of common botanical extracts and their pharmacology in the context of disease pathology. It might provide the information, for instance, required to void sub-fractions in the natural substance that may oppose a desired pharmacology or may produce a toxic outcome. It provides a better pharmacology fingerprint for the sub-fraction components needed to design compounding or synergistic activity, say in the case of a signalling pathway being influenced at multiple compounding points.

Latest News

New Curcumin Ingredient Aims for High Level of One Specific Curcuminoid to Boost Anti-Inflammatory Activity

Date: 03-16-2017 | 0: Comment

October 28, 2016 | Herbs & Botanicals, Science By Jennifer Grebow A new curcumin extract now being marketed under the brand name Curcumin BDM30 was developed with high levels of one particular curcuminoid: bisdemethoxycurcumin (BDMC). Due to its high...

Read more

Review of Amyotrophic Lateral Sclerosis, Parkinson’s and Alzheimer’s diseases helps further define pathology of the novel paradigm for Alzheimer’s with heavy metals as primary disease cause.

Date: 10-18-2016 | 1: Comment

Franco Cavaleri (as seen in Elsevier’s Medical Hypotheses) Faculty of Medicine, Department of Experimental Medicine, Brain Research Center, UBC Hospital, 2211 Wesbrook Mall, Vancouver, BC V6T 2B5, Canada http://www.medical-hypotheses.com/article/S0306-9877(15)00380-1/references Abstract Pathologies of neurological diseases are increasingly recognized to have common...

Read more

New biomedical research released today jointly by The Rhema Group and Biologic Pharmamedical

Date: 10-17-2016 | 0: Comment

New Curcumin Extract Found to Counteract Inflammation At the Transcriptional Level 05-Oct-2016 Vancouver, CANADA, April 17, 2017 – New biomedical research discovery released today shows that a trace component of the standard curcumin extract, bisdemethoxycurcumin (BDMC), is shown by...

Read more